Brief: Tasly Pharmaceutical's Unit Signs C-REV License Agreement With Japan's Takara Bio
11/05/2020 11:43
May 11 (Reuters) - Tasly Pharmaceutical Group Co Ltd
600535.SS :
* SAYS ITS UNIT OBTAINS EXCLUSIVE RIGHT IN CHINA TO PRODUCE
AND
COMMERCIALIZE PANCREATIC CANCER AND MELANOMA TREATMENT C-REVENUE
DEVELOPED BY JAPAN'S TAKARA BIO
Source text in Chinese: https://bit.ly/3drHhrk
Further company coverage: 600535.SS 4974.T
(Reporting by Hong Kong newsroom)
((twinnie.siu@thomsonreuters.com; 852-2841 5763;))